skip to Main Content

Growth Capital for Greiz High-Tech Company : bm|t and VACT AG invest in AVISO

  • 2007

bm|t beteili­gungs­man­age­ment thürin­gen gmbh, man­age­ment com­pany of the PET Pri­vate Equity Thürin­gen GmbH & Co. KG fund and VACT AG acquire a minor­ity stake in Greiz based com­pany AVISO GmbH. The pro­vided cap­i­tal will be used for launch­ing AVISO’s new “CellCelector”product line.

Dr. Guido Bohnenkamp, Gen­eral man­ager of bm|t, states that “ the sus­tain­able prod­uct devel­op­ment, the close coöper­a­tion with uni­ver­si­ties and research insti­tutes as well as the pro­found pro­fes­sional expe­ri­ence of the com­pany founder and for­mer sole share­holder Rein­hard Her­rmann were cru­cial ele­ments of our deci­sion to invest in AVISO”.

Accord­ing to Frank Hanser, exec­u­tive chair­man of the VACT AG, this deci­sion is “an unique pos­si­bil­ity to invest into a ben­e­fi­cial and highly inno­v­a­tive com­pany. This effi­ciently struc­tured busi­ness enables us simul­ta­ne­ously to sup­port the devel­op­ments for the col­lec­tive goods, e.g. in regen­er­a­tive medicine.”

Within a few years, the AVSIO-Team suc­ceeded in devel­op­ing a world­wide unique tech­nol­ogy for cell bio­log­i­cal research. The Cell­C­elec­tor and other sys­tems, that are still in the state of devel­op­ment, sup­port the stud­ies in regen­er­a­tive med­i­cine and in can­cer research. One of the first and impor­tant cus­tomers is the US Amer­i­can White Head Insti­tute who is cur­rently mak­ing world news with its achieve­ments in repro­gram­ma­ble somatic cells to stem cells.

When regen­er­a­tive med­i­cine has reached a state in which skin, car­ti­lage or organs can be grown of human somatic cells and trans­planted, then we are able to allay pain and to abort dis­eases. Con­se­quently, we can restore many people’s qual­ity of life. Within this large field of prospects AVISO aims to launch tech­nolo­gies that per­mit research and indus­try to faster achieve valu­able results”, CEO Rein­hard Her­rmann says. At present, AVISO main­tains research coöper­a­tion to many uni­ver­si­ties and insti­tutes. This close net­work enables AVISO to directly imple­ment cus­tomer demands into the research and devel­op­ment process and ulti­mately gain a per­ma­nent com­pet­i­tive advantage.


AVISO is a com­pe­tent part­ner for the devel­op­ment and pro­duc­tion of inno­v­a­tive sys­tems for lab­o­ra­tory automa­tion. With the focus on niches with great growth poten­tial within the biotech­nol­ogy branch AVISO devel­ops its inno­va­tions in close coöper­a­tion with cus­tomers and research insti­tutes in Europe, Asia and North­ern Amer­ica. Result­ing from this part­ner­ship are prod­ucts with highly inter­na­tional mar­ket accep­tance. In 2005, the AVISO has taken over the automa­tion branch of the MWB Biotech AG and thereby increased its port­fo­lio of liq­uid han­dling sys­tems. The com­pany oper­ates on the mar­kets in Ger­many, UK, and France and in the US with an own ser­vice and sales struc­ture. More­over, the AVISO is a long-time expe­ri­enced part­ner in OEM busi­ness. Together with its cus­tomers they develop and pro­duce assem­blies and instru­ments which are in use all over the world.

About VACT

VACT has devel­oped an equity and mez­za­nine prod­uct “Fasz­i­na­tion Mit­tel­stand” that focuses on small and medium sized busi­nesses in Ger­many. The com­pany has invested in indus­tries such as secu­rity and com­mu­ni­ca­tions, ser­vices, med­ical engi­neer­ing and energy and envi­ron­men­tal technology.


Ver­ena Büch
Assis­tant to Management

Tal­strasse 44
D‑07545 Gera
+49 365 55 191–42
+49 365 55 191–43

Man­ag­ing board
Frank K. M. Hanser

Erdinger Straße 84
D‑85356 Freis­ing
+49 8161 23471–0
+49 8161 23471–9

Back To Top
×Close search